Treatment decisions in AML: Personalizing care with FLT3 inhibitor therapy

During a meeting of the AML Hub Steering Committee, held on February 19, 2026, Jorge Sierra chaired a discussion on the topic, Treatment decisions in acute myeloid leukemia (AML): Personalizing care with FLT3 inhibitor therapy. The discussion featured contributions from Charles Craddock, Jorge Cortes, Hee-Je Kim, Jeffrey Lancet, Yasushi Miyazaki, Uwe Platzbecker, Roland Walter, and Agnieszka Wierzbowska.

This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.